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Isolation and characterization of complement receptor type 1 from rat
glomerular epithelial cells. Complement receptor type 1 (C3b/C4b re-
ceptor, CR1) is known to be present in human glomerular epithelial cells
(GEC) in vivo. The presence of CR1 has not been documented in rat
glomeruli, although cultured rat GEC appear to express CR1 based
upon their ability to rosette with complement-coated erythrocytes. In
this study, we establish that CR1 is present in cultured rat GEC: (1) by
isolating a 200 kDa protein from detergent-solubilized cultured rat GEC
through the use of C3b affinity chromatography; (2) by Western blotting
studies demonstrating reactivity of anti-human CR1 antibodies with this
protein from cultured GEC; and (3) by demonstrating that C3b binding
to GEC monolayers exhibits low affinity and that an estimate of the
number of binding sites is 6700 per cell, both of which are comparable
to that seen for CR1 in human blood cells. Furthermore, we show that
CR1 is also present in rat glomeruli by Western blotting studies with
anti-human CR1. Anti-human CR1 also identifies a 70 kDa protein from
cultured GEC and isolated glomeruli. This 70 kDa protein is likely to be
the CR1-like protein, designated Crry, which was initially identified in
the mouse and has significant homology to human CR!. Crry may be
present in rat GEC instead of decay accelerating factor, which is
present in human GEC.
In 1953, Nelson showed that microorganisms coated with
complement bound to human erythrocytes, a phenomenon
known as "immune adherence" [1]. Immune adherence recep-
tors were later identified in human glomeruli [21. These recep-
tors were subsequently localized to human glomerular epithelial
cells (GEC) in vivo [31 as well as GEC grown in culture [4]. The
receptor responsible for immune adherence, complement re-
ceptor type 1 (C3bIC4b receptor, CR1), was purified by Fearon
in 1979 from NP-40 solubilized human erythrocyte membranes
[51. The glomerular immune adherence receptor was docu-
mented to be CR1 using specific anti-CR! antibodies on human
kidney specimens [6]. Recently, the mRNA for CR! has been
localized to human GEC by in situ hybridization [7]. Cultured
rat GEC have also been shown to have immune adherence
receptors, based upon positive rosetting with complement-
coated erythrocytes [8, 9]. The role of CR1 in the glomerulus is
unknown. It has been postulated that GEC CR1 plays a role in
clearing immune complexes and/or that it may locally inhibit
complement activation [10]. There have been a number of
Received for publication November 30, 1992
and in revised form December 31, 1992
Accepted for publication December 31, 1992
© 1993 by the International Society of Nephrology
studies using rosetting or immunostaining techniques that have
shown alterations in CR! in human renal disease [6, 11—17].
From these studies, it appears that the expression of CR1
protein is diminished in proliferative glomerular diseases, but a
consistent pattern among other disease types has not yet
emerged.
In this study, we isolated a protein of 200 kDa by subjecting
detergent-solubiized cultured rat GEC to C3b affinity chroma-
tography. This is similar to the size of CR! from humans [5] and
the analogous murine protein [!8}, and therefore appears to be
rat CR1. This is the first instance that CR1 has been isolated
directly from GEC of any species. Antibodies directed towards
human CR1 reacted with a 200 kDa protein from both cultured
rat GEC and isolated glomeruli by Western blotting, confirming
that CR1 is present in rat GEC as well as in glomeruli in vivo. In
addition, anti-human CR1 reacted with a 70 kDa protein from
GEC and glomeruli. This 70 kDa protein is likely to be the
CR1-like protein, designated Crry, which was intitially identi-
fied in the mouse, and is homologous to human CR! [!9—2!].
We further show that the C3b binding characteristics of CR1 in
cultured GEC are similar to those of human CR1.
Methods
Preparation of rat C3b, dimeric C3b, and C3b-thiopropyl-
Sepha rose
Rat C3 was purified by a modification of the protocol of Basta
and Hammer [22]. Plasma collected from normal Sprague-
Dawley rats was brought to 5% (wt/vol) in polyethylene glycol
(average molecular weight = 3350, Sigma Chemical Co., St.
Louis, Missouri, USA). After centrifugation for 15 minutes at
!5,000 X g, the supernatant was precipitated with 11% polyeth-
ylene glycol. Following centrifugation, the precipitate was
resuspended in buffer containing 50 mM NaC1, 20 mM Tris, 33
mM e-amino-n-caproic acid, 6.5 mr'i benzamidine, 6.5 mM
EDTA, 5 m diisopropyl fluorophosphate (all from Sigma), pH
7.3, and applied to a 3 x 46 cm column of Q Sepharose Fast
Flow (Pharmacia Fine Chemicals, Piscataway, New Jersey,
USA). After washing with the starting buffer, a linear gradient
of NaC1 was applied. C3 was eluted with 130 to 190 mrt NaCI.
By sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) under reducing conditions, the a and /3 chains of
C3 had calculated molecular weights of 112 and 68 kDa,
respectively (Fig. !A), while under non-reducing conditions, C3
had a molecular weight of 179 kDa (Fig. 1B, lane 1).
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Fig. 1. SDS-PAGE of rat C3 reagents. A. Rat C3 electrophoresed under reducing conditions. The a and p chains of rat C3 are indicated on the
right. B. Rat C3 (lane 1), C3b (lane 2), and dimeric C3b (lane 3) electrophoresed under non-reducing conditions. C. C3 products released from
C3b-thiopropyl-Sepharose under reducing conditions. The a' and /3 chains of C3b are indicated on the right. The arrows show the 71 and 34 kDa
fragments of the C3bi a' chain. All gels were composed of a 4 to 12% acrylamide gradient and were stained with Coomassie Blue. The positions
of the mol wt markers are indicated on the left in each figure.
C3b was generated from C3 by incubation in 1.7% (wt/wt)
trypsin (TPCK-treated, type XIII, Sigma) for one minute at
37°C, following which a fourfold molar excess of soybean
trypsin inhibitor was added. To form dimeric C3b (C3bdim), the
homobifunctional sulfhydryl cross-linker, bismaleimidohexane
(Pierce Chemical Co., Rockford, Illinois, USA) was added at a
2½-fold molar excess to C3b. For this procedure, C3b was at 20
to 30 mg/ml in 145 mM NaC1, 5 mi Na barbital, pH 7.3,
containing 10% DMSO, to promote the solubility of bismaleim-
idohexane. The reaction was carried out on ice for two hours.
C3bdim was separated from monomeric C3b by size exclusion
chromatography on Superose 6 (Pharmacia), and both are
shown by SDS-PAGE in Figure lB (lanes 3 and 2, respectively).
The calculated molecular weight of monomeric C3b was 166
kDa. The concentrations of C3b and C3bdjm were determined
by measuring the 0D280, and using the human C3 extinction
coefficient of 9.7 [23].
C3bdim was labeled with 125J to an activity of 1.7 x 106
cpm!jg using Na1251 (Amersham Corp., Arlington Heights,
Illinois, USA) and immobilized lactoperoxidase (lodobeads,
Pierce) [24]. Free 1251 was separated from 125IC3bdjm by gel
filtration over a column of Sephadex G-25 (Pharmacia). The
25IC3bdim preparation was 97.2% precipitable with 10%
trichloroacetate.
C3b was bound via its free sulihydryl group to thiopropyl-
Sepharose (Pharmacia) as follows. Forty mg C3 was incubated
in 0.67 mg trypsin for one minute at 37°C followed by neutral-
ization with 2.67 mg soybean trypsin inhibitor. The resultant
C3b was incubated with 12 ml of thiopropyl-Sepharose in
phosphate buffered saline (PBS, 100 mr'r NaCl, 20 m Na
phosphate; pH 7.3) containing 1 mM EDTA for three hours at
room temperature. This was then poured into a 1 x 20 cm
column and washed by gravity with 500 mrs NaC1, 20 m Na
phosphate, 1 mrvi EDTA followed by PBS containing 1 mM
EDTA. Approximately 30 mg C3b remained bound to thiopro-
pyl-Sepharose (as judged by measuring the 0D280 of unbound
material). Twenty five d of a 50% suspension of C3b-thiopro-
pyl-Sepharose was boiled in SDS-PAGE reducing sample buffer
and electrophoresed on a 4 to 12% gradient acrylamide gel. As
shown in Figure lC, the a' (107 kDa) and /3(64 kDa) chains
were bound to the column. The minor proteins at 71 and 34 kDa
(arrows) presumably are cleavage products of the a' chain
(thereby forming C3bi [25]).
Antibody to human CR1
A polyclonal rabbit antibody to human CR1 (anti-CR 1) was
obtained from Bioproducts for Science (Indianapolis, Indiana,
USA). The globulin fraction (Ig) of anti-CR1 was isolated by
ammonium sulfate precipitation followed by dialysis against
PBS [26]. Western blotting (see below) of NP-40 solubilized
human polymorphonuclear leukocytes (isolated from a single
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to the manufacturer's instructions), revealed that anti-CRI
specifically reacted with a 183 kDa protein, which represents
the most common phenotype of human CR1 (CR1-A) [27].
GEC culture
Rat GEC were cultured in K! medium, which is Dulbecco's
Modified Eagle Medium/Ham's Nutrient Mixture F-b (1:1)
(GIBCO, Grand Island, New York, USA), containing 5%
Nu-Serum (Collaborative Research, Bedford, Massachusetts,
USA) and hormone supplements [281. These cells have been
previously characterized [28] and were used between passages
14 and 30. For the isolation of CR!, cells were grown in 100 mm
culture dishes on a type I collagen gel (Vitrogen, Collagen
Corp., Palo Alto, California, USA), while for C3b binding
studies, cells were grown to confluency on a thin collagen film
[29] in 24-well culture dishes.
Isolation of GEC CR1
Once GEC were confluent in 100 mm culture dishes, the
medium was removed and the cells were washed twice with
PBS. Cells were then removed with the adherent collagen,
which was digested with collagenase (type V, Sigma) at I mg/mi
in PBS for 20 minutes at 37°C. GEC were then washed with PBS
and solubilized in buffer containing 100 mM NaCI, 20 mM
bis-Tris, 10 mivi EDTA, 10 mrvi iodoacetamide, 5 m'vi diisopro-
pyl fluorophosphate (all from Sigma), 1% NP-40 (Calbiochem,
La Jolla, California, USA), pH 7.0, for 15 minutes on ice.
Nuclei and cellular debris were pelleted by centrifugation at
3000 x g for 10 minutes at 4°C. To promote binding to C3b, the
ionic strength and detergent concentration of the supernatant
were lowered to a final concentration of 50mM NaCl, 10mM Na
phosphate (½ PBS), 0.1% NP-40 by addition of H20 and PBS
[181. The solubilized GEC proteins were then applied to a
column of rabbit IgG coupled to cyanogen bromide-activated
Sepharose (to remove non-specifically bound material) followed
by passage over C3b-thiopropyl-Sepharose. After washing with
'/2 PBS, 0.1% NP-40, material specifically bound to the C3b
column was eluted with 500 mM NaCi, 20 m Na phosphate,
0.1% NP-40.
Cell membrane protein fragments were obtained by
trypsinization of intact cells. Cultured GEC were isolated as
described above and then incubated in PBS containing 0.1
mg/mi trypsin for 45 minutes at 37°C. Soybean trypsin inhibitor
was then added at 0.4 mg/mi, and cells were centrifuged at
15,000 X g. The supernatant, containing membrane protein
fragments, was diluted in half with H20, and then subjected to
C3b affinity chromatography as before, except that the eluting
buffer did not contain NP-40.
Isolation and solubilization of glomeruli
Giomeruli from the kidneys of two adult male Sprague-
Dawley rats were isolated by differential sieving [281. Glomeruli
were washed in PBS, solubilized in PBS containing 10 mM
EDTA, 10 mrvi iodoacetamide, 5 mivi diisopropyl fluorophos-
phate, and 1% NP-40 on ice for five minutes, and centrifuged at
3000 x g for 10 minutes. The supernatant, containing solubi-
lized glomerular proteins, was used for Western blotting.
Western blotting
Proteins were separated by SDS-PAGE and then electro-
phoretically transferred to a nitrocellulose membrane. The
nitroceilulose was cut into identical sections and blocked in 3%
(wt/vol) non-fat milk in 500 mivi NaC1, 20 mivi Tris, 0.05%
Tween-20, pH 7.4. The sections were then incubated with either
anti-human CR1 Ig, or non-immune rabbit Ig as a control, at 0.1
mg/mi in the same buffer for one hour at room temperature.
Following washing, bound rabbit IgG was detected with alka-
line phosphatase-conjugated goat anti-rabbit IgG which was
developed with both 5-bromo-4-chloro-3-indolyl phosphate and
nitro-biue tetrazolinium (Bio-Rad Laboratories, Richmond,
California, USA).
C3b binding studies in GEC
Confluent GEC in 24-well culture dishes were washed three
times with cold Hank's balanced salt solution (HBSS, GIBCO)
containing 0.1% (wt/vol) bovine serum albumin (BSA). Cells
were then incubated with '25IC3bdjm with or without unlabeled
C3b (Results) in HBSS/1% BSA (0.2 mi/well) for 60 minutes on
ice with continuous shaking. GEC were subsequently washed
twice with HBSS/0.b% BSA and twice with HBSS alone, and
then solubilized with 0.1 N NaOH (0.5 ml/weil). Bound 125J
C3bäim was counted in a gamma counter. Non-specific binding
was determined in parallel by addition of '251•C3bdim to wells
without cells, and these values (< 100 cpm) were subtracted
from all measurements. Total protein in each well was deter-
mined by the bicinchoninic protein assay (micro-BCA, Pierce),
after dilution with 0.02 M HC1 (0.7 ml added to 0.3 ml cell
protein). Data are expressed as ng '25IC3bdim bound per mg
cell protein. To determine the number of cells per mg protein,
cells were released with trypsin-EDTA [281 and counted in a
hemocytometer, and in parallel wells, protein concentration
was measured. There were 2.9 x 106 cells per mg protein as
determined by this technique.
Results
Isolation of CR1
Confluent GEC from ten 100 mm culture dishes (approxi-
mately 5 x iO cells) were solubilized with NP-40 and subjected
to C3b affinity chromatography. As shown in Figure 2, by
SDS-PAGE under non-reducing conditions, the major protein
band isolated by this technique migrated at a molecular weight
of 200 kDa (arrow). Identical results were obtained when the
sample was reduced (not shown), indicating that it is composed
of a single chain. Given the similarity in size to human and
murine CR! (190 to 210 kDa) [5, 18, 21], this protein obtained by
C3b affinity chromatography appears to be rat CR1.
With storage at 4°C or at —70°C, rat CR! appeared to
aggregate, as judged by SDS-PAGE that showed a progressive
loss of the 200 kDa protein band and the appearance of a protein
band that barely entered the gel. We felt this was most likely
due to hydrophobic interactions. Therefore, we sought to
isolate tryptic fragments of CR! that retained C3b binding
activity using a strategy that has worked for human CR1 [30].
GEC from forty 100 mm culture dishes were treated with
trypsin and the isolated membrane protein fragments were
subjected to C3b affinity chromatography. As shown in Figure
3, a prominent protein band of 59 kDa (large arrow), and smaller
quantities of 28, 20, and 13 kDa proteins (small arrows), were
recovered by C3b affinity chromatography of trypsinized GEC
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Fig. 2. Isolation of CR] from GEC by C3b affinity chromatography.
Cultured rat GEC were solubilized in detergent and applied to a
C3b-thiopropyl-Sepharose column. After washing, material specifically
bound to the column was eluted with buffer containing 500 mat NaC1,
and subsequently electrophoresed on a 7.5% acrylamide gel under
non-reducing conditions. Proteins were stained with Coomassie blue.
The arrow indicates the position of the 200 kDa CR1. The locations of
the mol wt markers are shown on the left.
membrane proteins. Therefore, several tryptic fragments of
GEC CR1 retain C3b binding activity.
C3b binding to GEC
In preliminary studies, the affinity of monomeric C3b for
GEC was too low to permit accurate assessment of CR1. This
low affinity is similar to that observed for human CR1 [3 1—33].
Therefore, we used dimeric C3b instead, which was originally
developed by Arnaout et al to assess human CR1 binding
characteristics [32]. t25IC3bdim at 5 flM was added to GEC in
the presence of incremental concentrations of unlabeled mono-
meric C3b. '25IC3bdm bound to CR! on GEC and unlabeled
monomeric C3b competed with 125IC3bdjm in a dose-dependent
fashion (Fig. 4). As determined in these experiments, binding of
125IC3bdim in excess monomeric C3b (> 3 /.LM) was approxi-
mately 5.0 ng!mg cell protein (Fig. 4). Taking this as non-
specific binding, GEC specifically bound 10.6 ng 125I-C3bj/mg
cell protein. As this appeared to be in excess C3bdjm (bound!
free concentration = 0.0036), an estimate of the number of CR!
molecules was then calculated to be at least 6700 per cell
(assuming each C3bdjm molecule bound to only one CR1). The
concentration at which monomeric C3b inhibited 50% of spe-
cific binding of 1251C3bdjm to GEC was 0.25 sM, which is the
same as that measured for human CR! [32].
Fig. 3. C3b affinity chromatography of GEC membrane protein tryptic
fragments. Cultured rat GEC were treated with trypsin, and the
resultant membrane protein fragments recovered in the supernatant
were subjected to C3b affinity chromatography. Specifically bound
fragments were eluted from the column with 500 mat NaCl and
electrophoresed on a 5 to 15% gradient acrylamide gel under non-
reducing conditions. Proteins were stained with Coomassie blue. By
C3b affinity chromatography, a prominent protein band of 59 kDa (large
arrow), and smaller quantities of 28, 20, and 13 kDa proteins (small
arrows) were recovered. The positions of the mol wt markers are shown
on the left.
Western blotting
As shown in Figure 5, anti-human CR! specifically reacted
with a protein of approximately 200 kDa from NP-40 solubilized
GEC (lane 2, long arrow). Therefore, human and rat GEC CR1
have immunological similarities. In addition, solubilized rat
glomeruli (lane 1) have immunoreactive CR1. CR1 isolated by
C3b affinity chromatography from NP-40 solubilized GEC (Fig.
2) was also identified by anti-human CR! (not shown). Interest-
ingly, anti-human CR! identified a protein of 70 kDa from
glomeruli and GEC (short arrow). This 70 kDa protein may
represent Crry, a murine homologue of human CR1 [19, 21, 34],
that has recently been shown to be present in the rat [35].
The tryptic fragments of GEC CR! were also subjected to
Western blotting with anti-human CR1. Interestingly, as shown
in Figure 6 (lane 1), anti-human CR1 did not react with the 59
kDa fragment isolated by C3b affinity chromatography (com-
pare with Fig. 3, large arrow), yet did react with the smaller
fragments (depicted by the small arrows in Fig. 3). Thus, rat
GEC CR1 appears to have C3b binding site(s) with immunolog-
ical similarity to human CR1, as well as at least one site that is
immunologically different from human CR1.
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Fig. 4. C3b binding to GEC. '25IC3bdim was added at 5 nM to confluent
monolayers of cultured rat GEC in the presence of incremental concen-
trations of monomeric C3b. Non-specific binding of '25IC3bdim to wells
without cells was subtracted from all values. Data are expressed as ng
'25lC3bdim bound per mg cell protein. Each point represents the
average of two determinations from two separate experiments.
Discussion
In this study, we have purified a C3b binding protein from
cultured rat GEC that is composed of a single 200 kDa chain
(Fig. 2). That this is CR1 comes from its similarity in size to the
homologous human and murine proteins [5, 181, and that it is
identified by antibody directed towards human CR! (Fig. 5).
Furthermore, the binding characteristics of C3b to cultured
GEC (Fig. 4) are similar to that seen in human blood cells, in
that CR1 has a low affinity for monomeric C3b, but a higher
affinity for dimeric (or polymeric) C3b [31—33]. Because CR! is
the predominant membrane protein isolated by C3b affinity
chromatography (Fig. 2), it is likely that these studies measure
C3b binding to CR1 alone (as has been inferred from similar
studies in human hematopoietic cells [31—33]). The finding of
6700 receptors per cell presumably reflects those receptors
present only on the apical surface of GEC as studies were
performed in monolayer culture. These receptor numbers are
comparable to that seen in unstimulated human nucleated blood
cells (5500 to 30,000 per cell) [32, 331.
C3b receptors have been identified in cultured rat GEC by
rosetting studies with erythrocytes coated with mouse [81 or
human complement [9]. In fact, the presence of C3b receptors
on cultured rat GEC was included by Kreisberg, Hoover, and
Karnovsky as a distinguishing characteristic of this cell type [8].
Still, not all investigators have found C3b receptors on cultured
rat GEC [36]. The strengths in the present study lie in our use
of pure rat C3 (Fig. 1), which obviates any species incompati-
bility that can occur in complement-receptor interactions [24].
In the studies by Kasinath et al, the presence of C3d receptors
(that is, CR2) in cultured rat GEC was inferred by rosetting with
erythrocytes bearing mouse C3d. We did not specifically seek
the presence of CR2 in GEC, although the C3b-thiopropyl-
Sepharose column contained C3bi (Fig. 1C), as an inevitable
consequence of the trypsinization protocol. Although C3bi is a
ligand for all C3 receptors (CR1, CR2, CR3, CR4) [37], we only
isolated CR1 by affinity chromatography on this column.
CR1 has been identified in human glomeruli by a variety of
techniques, including rosetting studies [2—4], immunochemical
studies [6, 16], direct purification [38], and by in situ hybridiza-
tion [7]. Yet, despite the presence of CR1 on rat GEC in culture,
investigators have been unable to identify CR1 in rat glomeruli,
as assessed by erythrocyte rosetting [2, 13]. To our knowledge,
the current finding of immunoreactive CR! in rat glomeruli (Fig.
5) is the first instance that it has been demonstrated in this site.
It is unclear why glomeruli from rats (as well as from other
diverse species) do not rosette with C3b-coated erythrocytes
[2]. One explanation may be that human GEC express much
higher quantities of CR1 than do those of other species, which
is suggested by the studies of Fischer et al, who obtained an
estimate of 200,000 CR1 molecules per human GEC [38].
In common to all of the known C3 binding proteins is a highly
conserved, 60 amino acid short consensus repeat (SCR) that
confers C3 binding activity. For example, there are 30 SCRs in
the most common allotype of human CR1 [39]. Because of this
repetition, there are multiple binding sites for C3b on human
CR! [39]. Studies by Klickstein et al showed that two SCRs
determined specificity for C3b binding [39]. More recent inves-
tigations by this group have shown that three or four SCRs
appear to be required for optimal binding to C3b [40]. In this
study, we show that rat CR1 tryptic fragments of 28, 20, and 13
kDa retained C3b binding activity (Fig. 3), and were immuno-
logically similar to human CR1, based upon their reactivity with
anti-human CR! (Fig. 6). It is likely that even the 13 kDa
fragment includes at least two SCRs (as well as part of a third
SCR), which illustrates that two or three SCRs alone can bind
C3b. Interestingly, the 59 kDa fragment that was recovered
from C3b-thiopropyl-Sepharose (Fig. 3) did not react with
anti-human CR!, which points out probable dissimilarities
between human and rat CR!.
Recently, the biology of complement receptors in the mouse
has been described. The mouse has two proteins of 190 to 210
and 60 to 70 kDa, termed MCR1 (or Cr2) and Crry (or p65),
respectively, that have homology to human CR! [18—21, 41].
MCR1 also has significant homology to human CR2 [20, 34],
and appears to arise via the addition of 6 CR1-like SCRs onto
the N-terminus of a CR2-like protein [41]. Still, MCR1 functions
as CR1 does in humans, and retains its C3b binding activity [18,
34, 42]. The localization of this protein is more limited than its
human counterpart, in being present on B lymphocytes and
peritoneal macrophages, but not on erythrocytes or unstimu-
lated neutrophils [42]. The renal distribution of MCR1 in the
mouse has not been reported. Whether the 200 kDa C3b binding
protein from rat GEC and glomeruli that we have termed CR! is
homologous to MCR! awaits further investigation.
Rat glomeruli and cultured GEC also contained a 70 kDa
protein that was identified by anti-human CR! (Fig. 5). It is
likely that this represents Crry (p65), that initially was identified
in the mouse via its reactivity with anti-human CR! [21].
Recently, Crry mRNA has been identified in rat neural tissue
[35]. That this 70 kDa protein was not purified by C3b affinity
chromatography from solubilized rat GEC (Fig. 2) is consistent
with the results of other investigators [18]. We have previously
shown that decay accelerating factor is present in human
glomeruli and on human GEC, where it is functionally active,
but we could not identify it by immunological means in rat GEC
[24]. In the mouse, the gene for decay accelerating factor is
absent, leading to the conclusion that Crry may be its functional
analogue [34]. Thus, our results suggest that rather than having
decay accelerating factor, as human GEC do, rat GEC contain
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Fig. 5. Western blotting of rat GEC and
gloineruli with anti-human CR]. Cultured rat
GEC (lanes 2 and 4) and isolated rat glomeruli
(lanes 1 and 3) were detergent solubilized,
electrophoresed on a 4 to 12% gradient
acrylamide gel, and transferred to
nitrocellulose. Western blotting was
performed with anti-human CR1 Ig (lanes I
and 2), or non-immune rabbit Ig (lanes 3 and
4). Anti-CR1 specifically identified proteins of
approx 200 kDa (long arrow) and 70 kDa
(short arrow). The positions of the mol wt
standards are indicated on the left.
In conclusion, we have documented that CR1 is present in
cultured rat GEC and in isolated glomeruli. Rat GEC CR1 has
immunological similarities to human CR1, but also contains a 59
kDa tryptic fragment that is not identified by anti-human CR1.
The characteristics of GEC CR1 are comparable to that of
human blood cells in terms of C3b binding affinity and receptor
number. We have also shown that rat GEC and glomeruli
appear to contain Crry. The roles of CR1 and Crry in glomerular
complement regulation and immune complex processing are
currently unknown.
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